Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 9Observational 1

Sponsor

Cancer Type

Genitourinary 18Gastrointestinal 4Sarcoma 3Tumor-Agnostic 1NET 1Lymphoid 1Endocrine 1

Conditions

Pancreatic Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 6Magnetic Resonance Spectroscopy 3Data Collection 3telotristat ethyl 2surufatinib 2Somatostatin 2Positron-Emission Tomography 2Everolimus 2Drug Therapy 2Biopsy 2lanreotide 1copper dotatate CU-64 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Sorafenib 1Salvage Therapy 1Radionuclide Imaging 1Radiomics 1Radiofrequency Ablation 1Quality of Life 1Plastic Surgery Procedures 1Phlebotomy 1Patient Reported Outcome Measures 1Octreotide 1Molecular Diagnostic Techniques 1Lutetium-177 1Lutetium 1Liver Transplantation 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Sunitinib × NET × Clear all
NCT02282059 2024-06-20

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Pfizer

Completed
100 enrolled 13 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡